On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Stratec Biomedical AG Gemini. This instrumentation change is necessary as Bio-Rad is discontinuing service on our existing QuickStep instrumentation.
Although the Immucor assay and sample requirements will remain the same, the package insert has been modified to state the assay is specific to the Stratec Gemini instrument. The new package insert, assay history list, and platform history list will be available on the CTS website on 04/29/19.
On December 9, 2019, the new CTS Laboratory Information System successfully implemented in Phoe...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...